Beneficial Actions of Neurotrophin Treatment on Diabetes-Induced Hypoalgesia in Mice

Journal of Pain

Volumn 4, Issue 9, 2003, Pages 493-504

  Christianson, Julie A ^a   Ryals, Janelle M ^a   McCarson, Kenneth E ^b   Wright, Douglas E ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Behavior; GDNF; Neuropathy; NGF; Nociception

Indexed keywords

ACETONE; FORMALDEHYDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INSULIN; NERVE GROWTH FACTOR; NEUROTROPHIN; STREPTOZOCIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLD EXPOSURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; HEAT; HYPOALGESIA; INFLAMMATION; MECHANICAL STIMULATION; MOUSE; NOCICEPTION; NOCICEPTIVE STIMULATION; NONHUMAN; SENSORY DYSFUNCTION; SKIN SENSITIVITY; SPINAL GANGLION; STREPTOZOCIN DIABETES;

EID: 0348216687     PISSN: 15265900     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpain.2003.07.002     Document Type: Article

References (69)

1. Abbadie C, Taylor BK, Peterson MA, Basbaum Al: Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: Studies with remifentanil and lidocaine. Pain 69:101-110, 1997
2. Akkina SK, Patterson CL, Wright DE: GDNF rescues non-peptidergic unmyelinated primary afferents in streptozotocin-treated diabetic mice. Exp Neurol 167:173-182, 2001
3. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV: The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2:703-707, 1996
4. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA: Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 634:7-12, 1994
5. Apfel SC: Neurotrophic factors in peripheral neuropathies: Therapeutic implications. Brain Pathol 9:393-413, 1999
6. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck PJ: Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial- rhNGF Clinical Investigator Group. JAMA 284:2215-2221, 2000
7. Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV: Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur J Neurosci 7:1484-1494, 1995
8. Bennett DL, Averill S, Clary DO, Priestley JV, McMahon SB: Postnatal changes in the expression of the trkA high-affinity NGF receptor in primary sensory neurons. Eur J Neurosci 8:2204-2208, 1996
9. Boucher TJ, Okuse K, Bennett DL, Munson JB, Wood JN, McMahon SB: Potent analgesic effects of GDNF in neuropathic pain states. Science 290:124-127, 2000
10. Brown MJ, Sumner AJ, Greene DA, Diamond SM, Asbury AK: Distal neuropathy in experimental diabetes mellitus. Ann Neurol 8:168-178, 1980
11. Cain DM, Khasabov SG, Simone DA: Response properties of mechanoreceptors and nociceptors in mouse glabrous skin: An in vivo study. J Neurophysiol 85:1561-1574, 2001
12. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR: Tactile al-Iodynia and formalin hyperalgesia in streptozotocin-diabetic rats: Effects of insulin, aldose reductase inhibition and Iidocaine. Pain 68:293-299, 1996
13. Calcutt NA, Stiller C, Gustafsson H, Malmberg AB: Elevated substance-P-like immunoreactivity levels in spinal dialysates during the formalin test in normal and diabetic rats. Brain Res 856:20-27, 2000
14. Caterina MJ, Julius D: The vanilloid receptor: A molecular gateway to the pain pathway. Annu Rev Neurosci 24:487-517, 2001
15. Cesena RM, Calcutt NA: Gabapentin prevents hyperalgesia during the formalin test in diabetic rats. Neurosci Lett 262:101-104, 1999
16. Christianson JA, Riekhof JT, Wright DE: Beneficial effects of neurotrophin treatment on diabetes-induced cutaneous axon loss in mice. Exp Neurol 179:188-199, 2003
17. Courteix C, Eschalier A, Lavarenne J: Streptozocin-induced diabetic rats: Behavioural evidence for a model of chronic pain. Pain 53:81-88, 1993
18. Davis BM, Lewin GR, Mendell LM, Jones ME, Albers KM: Altered expression of nerve growth factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. Neuroscience 56:789-792, 1993
19. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
20. Dirig DM, Salami A, Rathbun ML, Ozaki GT, Yaksh TL: Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli. J Neurosci Methods 76:183-191, 1997
21. Dixon WJ: Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441-462, 1980
22. Faradji V, Sotelo J: Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand 81:402-406, 1990
23. Fernyhough P, Diemel LT, Hardy J, Brewster WJ, Mohiuddin L, Tomlinson DR: Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur J Neurosci 7:1107-1110, 1995
24. Fernyhough P, Diemel LT, Tomlinson DR: Target tissue production and axonal transport of neurotrophin-3 are reduced in streptozotocin-diabetic rats. Diabetologia 41:300-306, 1998
25. Fox A, Eastwood C, Gentry C, Manning D, Urban L: Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 81:307-316, 1999
26. Greene DA, Stevens MJ, Feldman EL: Diabetic neuropathy: Scope of the syndrome. Am J Med 107:2S-8S, 1999
27. Guo A, Vulchanova L, Wang J, Li X, Elde R: Immunocytochemical localization of the vanilloid receptor 1 (VR1): Relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 11:946-958, 1999
28. Guo A, Simone DA, Stone LS, Fairbanks CA, Wang J, Elde R: Developmental shift of vanilloid receptor 1 (VR1) terminals into deeper regions of the superficial dorsal horn: Correlation with a shift from TrkA to Ret expression by dorsal root ganglion neurons. Eur J Neurosci 14:293-304, 2001
29. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88, 1988
30. Hellweg R, Hartung HD: Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 26:258-267, 1990
31. Herrmann DN, Griffin JW, Hauer P, Cornblath DR, McArthur JC: Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology 53:1634-1640, 1999
32. Hirai A, Yasuda H, Joko M, Maeda T, Kikkawa R: Evaluation of diabetic neuropathy through the quantitation of cutaneous nerves. J Neurol Sci 172:55-62, 2000
33. Hunt SP, Rossi J: Peptide- and non-peptide-containing unmyelinated primary afferents: The parallel processing of nociceptive information. Philos Trans R Soc Lond B Biol Sci 308:283-289, 1985
34. Hylden JL, Wilcox GL: Intrathecal morphine in mice: A new technique. Eur J Pharmacol 67:313-316, 1980
35. Jakobsen J, Brimijoin S, Skau K, Sidenius P, Wells D: Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes 30:797-803, 1981
36. Jett MF, McGuirk J, Waligora D, Hunter JC: The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Pain 69:161-169, 1997
37. Kamei J, Ohhashi Y, Aoki T, Kasuya Y: Streptozotocin-induced diabetes in mice reduces the nociceptive threshold, as recognized after application of noxious mechanical stimuli but not of thermal stimuli. Pharmacol Biochem Behav 39:541-544, 1991
38. Kamei J, Hitosugi H, Kasuya Y: Formalin-induced nociceptive responses in diabetic mice. Neurosci Lett 149:161-164, 1993
39. Kamei J, Zushida K, Morita K, Sasaki M, Tanaka S: Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice. Eur J Pharmacol 422:83-86, 2001
40. Karanth SS, Springall DR, Francavilla S, Mirrlees DJ, Polak JM: Early increase in CGRP- and VIP-immunoreactive nerves in the skin of streptozotocin-induced diabetic rats. Histochemistry 94:659-666, 1990
41. Kerr BJ, Souslova V, McMahon SB, Wood JN: A role for the TTX-resistant sodium channel Nav 1.8 in NGF-induced hyperalgesia, but not neuropathic pain. Neuroreport 12:3077-3080, 2001
42. Knyihar-Csillik E, Bezzegh A, Boti S, Csillik B: Thiamine monophosphatase: A genuine marker for transganglionic regulation of primary sensory neurons. J Histochem Cytochem 34:363-371, 1986
43. Koltzenburg M, Stucky CL, Lewin GR: Receptive properties of mouse sensory neurons innervating hairy skin. J Neurophysiol 78:1841-1850, 1997
44. Lewin GR, Rueff A, Mendell LM: Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci 6:1903-1912, 1994
45. McCall WD, Tanner KD, Levine JD: Formalin induces biphasic activity in C-fibers in the rat. Neurosci Lett 208:45-48, 1996
46. Molliver DC, Radeke MJ, Feinstein SC, Snider WD: Presence or absence of TrkA protein distinguishes subsets of small sensory neurons with unique cytochemical characteristics and dorsal horn projections. J Comp Neurol 361:404-416, 1995
47. Molliver DC, Snider WD: The NGF receptor TrkA is down-regulated during postnatal development by a subset of dorsal root ganglion neurons. J Comp Neurol 381:428-438, 1997
48. Molliver DC, Wright DE, Leitner ML, Parsadanian AS, Doster K, Wen D, Yan Q, Snider WD: IB-4-binding DRG neurons switch from NGF to GDNF dependence in early postnatal life. Neuron 19:849-861, 1997
49. Mueller MJ: Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: Use of Semmes-Weinstein monofilaments. Phys Ther 76:68-71, 1996
50. Murray CW, Porreca F, Cowan A: Methodological refinements to the mouse paw formalin test: An animal model of tonic pain, J Pharmacol Methods 20:175-186, 1988
51. Navarro X, Kennedy WR: Evaluation of thermal and pain sensitivity in type I diabetic patients. J Neurol Neurosurg Psychiatry 54:60-64, 1991
52. Norrsell U, Eliasson B, Frizell M, Wallin BG, Wesslau C, Olausson H: Tactile directional sensibility and diabetic neuropathy. Muscle Nerve 24:1496-1502, 2001
53. Petruska JC, Streit WJ, Johnson RD: Localization of unmyelinated axons in rat skin and mucocutaneous tissue utilizing the isolectin GS-I-B4. Somatosens Mot Res 14:17-26, 1997
54. Puig S, Sorkin LS: Formalin-evoked activity in identified primary afferent fibers: Systemic Iidocaine suppresses phase-2 activity. Pain 64:345-355, 1996
55. Schmidt RE, Grabau GG, Yip HK: Retrograde axonal transport of [1251] nerve growth factor in ileal mesenteric nerves in vitro: Effect of streptozotocin diabetes. Brain Res 378:325-336, 1986
56. Shibata M, Ohkubo T, Takahashi H, Inoki R: Modified formalin test: Characteristic biphasic pain response. Pain 38:347-352, 1989
57. Silos-Santiago I, Molliver DC, Ozaki S, Smeyne RJ, Fagan AM, Barbacid M, Snider WD: Non-TrkA-expressing small DRG neurons are lost in TrkA deficient mice. J Neurosci 15:5929-5942, 1995
58. Silverman JD, Kruger L: Lectin and neuropeptide labeling of separate populations of dorsal root ganglion neurons and associated " nociceptor" thin axons in rat testis and cornea whole-mount preparations. Somatosens Res 5:259-267, 1988
59. Sima AA, Nathaniel V, Bril V, McEwen TA, Greene DA: Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 81:349-364, 1988
60. Snider WD, McMahon SB: Tackling pain at the source: New ideas about nociceptors. Neuron 20:629-632, 1998
61. Stucky CL, Koltzenburg M, Schneider M, Engle MG, Albers KM, Davis BM: Overexpression of nerve growth factor in skin selectively affects the survival and functional properties of nociceptors. J Neurosci 19:8509-8516, 1999
62. Takeshita N, Yamaguchi 1: Insulin attenuates formalin-induced nociceptive response in mice through a mechanism that is deranged by diabetes mellitus. J Pharmacol Exp Ther 281:315-321, 1997
63. Tomlinson DR, Fernyhough P, Diemel LT: Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 46:S43-S49, 1997
64. Vinik Al: Diabetic neuropathy: Pathogenesis and therapy. Am J Med 107:17S-26S, 1999
65. Wang Z, Dohle C, Friemann J, Green BS, Gleichmann H: Prevention of high- and low-dose STZ-induced diabetes with D-glucose and 5-thio-D-glucose. Diabetes 42:420-428, 1993
66. Xu M, Kontinen VK, Kalso E: Effects of radolmidine, a novel alpha2 -adrenergic agonist compared with dexmedetomidine in different pain models in the rat. Anesthesiology 93:473-481, 2000
67. Yeomans DC, Proudfit HK: Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: Electrophysiological evidence. Pain 68:141-150, 1996
68. Yeomans DC, Pirec V, Proudfit HK: Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: Behavioral evidence. Pain 68:133-140, 1996
69. Zwick M, Davis BM, Woodbury CJ, Burkett JN, Koerber HR, Simpson JF, Albers KM: Glial cell line-derived neurotrophic factor is a survival factor for isolectin B4-positive, but not vanilloid receptor 1-positive, neurons in the mouse. J Neurosci 22:4057-4065, 2002